A retrospective, single institution study of immunotherapy experience in malignant pleural mesothelioma
Latest Information Update: 28 Jul 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology